<DOC>
	<DOCNO>NCT00089908</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN1delta30 ) Healthy Adults</brief_title>
	<detailed_description>More 2 billion people live tropical subtropical region world risk dengue virus infection . Dengue viruses cause dengue fever , well severe dengue hemorrhagic fever/shock syndrome , dengue virus infection lead cause hospitalization death child several tropical Asian country . This study evaluate safety immunogenicity live , attenuate dengue virus call rDEN1delta30 , derive Western Pacific DEN1 serotype . This study last 180 day . Participants Cohort 1 randomly assign receive rDEN1delta30 placebo study entry . Cohort 2 begin safety review participant Cohort 1 . Participants Cohort 2 receive high dose rDEN1delta30 placebo . After vaccination , participant ask monitor temperature every day 16 day . Study visit occur every day vaccination Day 16 , follow 4 additional visit select day Day 180 . Blood collection target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing follow duration study Willing use acceptable method contraception Good general health Clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Liver , renal , hematologic disease Alcohol drug abuse within 12 month study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month study entry HIV1 infect HCV infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week study entry Killed vaccine within 2 week study entry Blood product within 6 month study entry Investigational drug vaccine within 60 day prior study entry currently enrol clinical trial Previously receive licensed experimental yellow fever dengue vaccine Surgical removal spleen History dengue virus infection flavivirus infection Other condition , opinion investigator , would affect participant 's participation study Pregnancy breastfeed Plan travel area dengue infection common</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>